Theseus Pharmaceuticals
Developing best-in-class kinase inhibitors to shape the future of targeted oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Theseus Pharmaceuticals is dedicated to revolutionizing cancer treatment by developing next-generation tyrosine kinase inhibitors (TKIs). These inhibitors are designed to target and inhibit all major cancer-causing and drug-resistant mutations in clinically significant tyrosine kinase targets. The company primarily serves cancer patients who are facing treatment resistance, a critical challenge in current cancer therapies. Operating in the biotechnology and pharmaceutical market, Theseus Pharmaceuticals employs a research-driven business model, focusing on the development and commercialization of innovative cancer treatments. Revenue is generated through the development and potential future sales of their proprietary TKIs, as well as possible partnerships and licensing agreements with larger pharmaceutical companies.
Keywords: cancer treatment, tyrosine kinase inhibitors, drug resistance, biotechnology, pharmaceutical, cancer mutations, innovative therapies, research-driven, commercialization, partnerships.